Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTR087 and SEA-BCMA in relapsed or refractory multiple myeloma
NCT03266692Phase 1Terminated
- Sponsor
- Cogent Biosciences
- Start
- Feb 2018
- Primary completion
- Oct 2019
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ACTR087 in multiple myeloma (MM), sponsored by Cogent Biosciences. Primary endpoints: Safety and tolerability of ACTR087 in combination with SEA-BCMA at 28 days and Recommended Phase 2 Dose at 52 weeks. Started Feb 2018; status: terminated.
02
Drugs
ACTR087
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03266692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03266692.